SPA
NRIX icon

Sherbrooke Park Advisers’s Nurix Therapeutics NRIX Stock Holding History

Sherbrooke Park Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,817
Closed -$99.9K – 431
2025
Q3 		$99.9K Buy
+10,817
New +$112K 0.05% 449

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sherbrooke Park Advisers's NRIX Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 10,817 shares — an estimated $99.9K sold.

Sherbrooke Park Advisers first reported a position in NRIX in Q3 2025 and held it in 1 quarter. The position peaked at $99.9K in Q3 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 10,817 Nurix Therapeutics shares in Q4 2025, an estimated $99.9K.
  • Sherbrooke Park Advisers first reported a position in Nurix Therapeutics in Q3 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Nurix Therapeutics position peaked at $99.9K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.